Cargando…
Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study
Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of lung cancer that is associated with the Epstein-Barr virus in Asia. Due to the lack of prospective studies, the best first-line treatment and survival outcomes remain unclear. Herein, This study investigated the efficacy and saf...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882604/ https://www.ncbi.nlm.nih.gov/pubmed/35237520 http://dx.doi.org/10.3389/fonc.2022.820302 |
_version_ | 1784659730426232832 |
---|---|
author | Xiao, Yi He, Jinyuan Luo, Shaoning Dong, Min Li, Wei Liu, Gaijiao Chen, Hongjie Yang, Xiongwen Huang, Shaohong |
author_facet | Xiao, Yi He, Jinyuan Luo, Shaoning Dong, Min Li, Wei Liu, Gaijiao Chen, Hongjie Yang, Xiongwen Huang, Shaohong |
author_sort | Xiao, Yi |
collection | PubMed |
description | Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of lung cancer that is associated with the Epstein-Barr virus in Asia. Due to the lack of prospective studies, the best first-line treatment and survival outcomes remain unclear. Herein, This study investigated the efficacy and safety of different treatment regimens for advanced pLELC. This retrospective study included 68 patients with advanced pLELC from two centers in China. Patients were divided into three groups according to different first-line treatments: chemotherapy (n=49, 72.1%), immunotherapy (n=7, 10.3%), and chemoimmunotherapy (n=12,17.6%). The primary endpoint of this study was the 2-year progression-free survival (PFS) of each group. The results show that the median PFS was 6.9 months (range, 2.3–not estimable) in the chemotherapy group, 11.0 months (range, 2–not estimable) in the immunotherapy group, and 11.8 months (range, 6–not estimable) in the chemoimmunotherapy group. There was a significant difference in 2-year PFS between the chemoimmunotherapy group and the chemotherapy group (hazard ratio, 0.38, 95% confidence interval: 0.18-0.78, log-rank P=0.007). The most frequent grade 3-4 adverse event in the chemotherapy and chemoimmunotherapy groups was myelosuppression (10/49 [22.4%] and 4/12 [33.3%], respectively). The most frequent grade 3-4 adverse events in the immunotherapy group were diarrhea (1/7, 14.8%) and hepatotoxicity (1/7, 14.8%). Chemoimmunotherapy had the highest 2-year PFS as a first-line treatment for advanced pLELC compared to chemotherapy and immunotherapy. This study suggests that chemoimmunotherapy may be the best first-line treatment for patients with advanced pLELC. |
format | Online Article Text |
id | pubmed-8882604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88826042022-03-01 Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study Xiao, Yi He, Jinyuan Luo, Shaoning Dong, Min Li, Wei Liu, Gaijiao Chen, Hongjie Yang, Xiongwen Huang, Shaohong Front Oncol Oncology Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare subtype of lung cancer that is associated with the Epstein-Barr virus in Asia. Due to the lack of prospective studies, the best first-line treatment and survival outcomes remain unclear. Herein, This study investigated the efficacy and safety of different treatment regimens for advanced pLELC. This retrospective study included 68 patients with advanced pLELC from two centers in China. Patients were divided into three groups according to different first-line treatments: chemotherapy (n=49, 72.1%), immunotherapy (n=7, 10.3%), and chemoimmunotherapy (n=12,17.6%). The primary endpoint of this study was the 2-year progression-free survival (PFS) of each group. The results show that the median PFS was 6.9 months (range, 2.3–not estimable) in the chemotherapy group, 11.0 months (range, 2–not estimable) in the immunotherapy group, and 11.8 months (range, 6–not estimable) in the chemoimmunotherapy group. There was a significant difference in 2-year PFS between the chemoimmunotherapy group and the chemotherapy group (hazard ratio, 0.38, 95% confidence interval: 0.18-0.78, log-rank P=0.007). The most frequent grade 3-4 adverse event in the chemotherapy and chemoimmunotherapy groups was myelosuppression (10/49 [22.4%] and 4/12 [33.3%], respectively). The most frequent grade 3-4 adverse events in the immunotherapy group were diarrhea (1/7, 14.8%) and hepatotoxicity (1/7, 14.8%). Chemoimmunotherapy had the highest 2-year PFS as a first-line treatment for advanced pLELC compared to chemotherapy and immunotherapy. This study suggests that chemoimmunotherapy may be the best first-line treatment for patients with advanced pLELC. Frontiers Media S.A. 2022-02-14 /pmc/articles/PMC8882604/ /pubmed/35237520 http://dx.doi.org/10.3389/fonc.2022.820302 Text en Copyright © 2022 Xiao, He, Luo, Dong, Li, Liu, Chen, Yang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xiao, Yi He, Jinyuan Luo, Shaoning Dong, Min Li, Wei Liu, Gaijiao Chen, Hongjie Yang, Xiongwen Huang, Shaohong Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study |
title | Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study |
title_full | Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study |
title_fullStr | Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study |
title_full_unstemmed | Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study |
title_short | Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma: A Retrospective Study |
title_sort | comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: a retrospective study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882604/ https://www.ncbi.nlm.nih.gov/pubmed/35237520 http://dx.doi.org/10.3389/fonc.2022.820302 |
work_keys_str_mv | AT xiaoyi comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT hejinyuan comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT luoshaoning comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT dongmin comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT liwei comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT liugaijiao comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT chenhongjie comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT yangxiongwen comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy AT huangshaohong comparisonofimmunotherapychemotherapyandchemoimmunotherapyinadvancedpulmonarylymphoepitheliomalikecarcinomaaretrospectivestudy |